Prospective Study of Treatment with Ensitrelvir for COVID-19 in Patients Undergoing Hemodialysis (PROTECT-HD)
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Patients on hemodialysis (HD) are vulnerable to COVID-19 and often excluded from pivotal antiviral trials. Ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor approved in Japan, remains unevaluated in patients undergoing HD. This study assesses the pharmacokinetics, antiviral activity, safety, and clinical effectiveness of ensitrelvir in participants with mild COVID-19 undergoing HD. In this prospective, single-arm, open-label study (December 2024–April 2025), participants with mild COVID-19 undergoing HD received ensitrelvir 375 mg on Day 1, followed by 125 mg once daily on Days 2–5. On Visit 2 (Day 3), plasma ensitrelvir concentrations were measured at three time points prior to ensitrelvir administration—before, during, and after dialysis. On Visit 3 (Day 5), blood samples were collected after dialysis and prior to ensitrelvir administration. Clinical outcomes, body temperature, SARS-CoV-2 viral load, and viral titers were monitored through Day 8. The primary endpoint was plasma concentration of ensitrelvir relative to dialysis; secondary endpoints included clinical outcomes, body temperature, and changes in viral load. Eight participants were evaluated: mean age, 68.1 years; mean body weight, 58.0 kg; and mean body mass index, 24.1 kg/m2. Plasma ensitrelvir concentrations (geometric mean) remained stable, with similar levels before (18.0 µg/mL) and after dialysis (16.4 µg/mL). All participants were judged clinically effective by the investigator by Day 8. Body temperature normalized within 16.6–48.0 h in four participants, and in one participant after 59.2 h. SARS-CoV-2 viral load (mean ± standard deviation) declined by 2.85 ± 1.52 log10 copies/mL from baseline to Day 8. No treatment-emergent adverse events, hospitalizations, or severe COVID-19-related complications occurred. No dose adjustment was required regardless of HD. In participants with mild COVID-19 undergoing HD, plasma ensitrelvir concentrations were similar to those previously reported in healthy individuals. Ensitrelvir showed favorable antiviral and clinical responses, supporting its safe use without dose adjustments. Japan Registry of Clinical Trials ID: jRCTs071240069. This study examined how a drug called ensitrelvir works in patients with mild COVID-19 who are on hemodialysis, a treatment for kidney failure. Hemodialysis is a process that filters waste, extra fluids, and toxins from the blood when the kidneys can no longer do so effectively. Ensitrelvir is an oral drug that helps stop the SARS-CoV-2 virus from multiplying. It is approved for use in Japan, but its effectiveness in patients on hemodialysis have not been studied. As patients on hemodialysis are often excluded from major drug trials, this study aimed to understand how the drug behaves in their bodies and how effective and safe it is. Eight participants took ensitrelvir for 5 days. The amount of the drug in their blood before, during, and after dialysis was measured to check if dialysis affected drug levels. Participants’ body temperature, the amount of virus in their bodies, and any side effects for 8 days were also monitored. The results showed that dialysis did not change the drug levels in the blood. Four of five participants who had a fever saw their temperature return to normal within 2 days. The amount of virus in the body reduced markedly over the study period. No serious side effects, hospitalizations, or severe COVID-19 cases were reported. These findings suggest that ensitrelvir can be effective in patients with COVID-19 undergoing hemodialysis. Ensitrelvir does not require dose adjustments, making it a promising treatment option for this vulnerable group.
Fields of Study & Subjects
COVID-19 Clinical Research Studies
SARS-CoV-2 and COVID-19 Research
Dialysis and Renal Disease Management
Publication details
- Journal / source
- Infectious Diseases and Therapy
- Volume
- 15
- Issue
- 5
- Pages
- 1451–1466
- Publication date
- 1 April 2026
- Language
- EN